Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Pliant Therapeutics (PLRX) over the last 7 years, with Q2 2025 value amounting to $112000.0.

  • Pliant Therapeutics' Capital Expenditures fell 9104.72% to $112000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $583000.0, marking a year-over-year decrease of 8424.32%. This contributed to the annual value of $3.8 million for FY2024, which is 31780.67% up from last year.
  • Pliant Therapeutics' Capital Expenditures amounted to $112000.0 in Q2 2025, which was down 9104.72% from $262000.0 recorded in Q1 2025.
  • Pliant Therapeutics' Capital Expenditures' 5-year high stood at $1.5 million during Q1 2024, with a 5-year trough of $61000.0 in Q4 2023.
  • Moreover, its 5-year median value for Capital Expenditures was $371000.0 (2021), whereas its average is $492000.0.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 85319.15% in 2024, then crashed by 9104.72% in 2025.
  • Pliant Therapeutics' Capital Expenditures (Quarter) stood at $592000.0 in 2021, then crashed by 71.96% to $166000.0 in 2022, then plummeted by 63.25% to $61000.0 in 2023, then surged by 242.62% to $209000.0 in 2024, then tumbled by 46.41% to $112000.0 in 2025.
  • Its Capital Expenditures stands at $112000.0 for Q2 2025, versus $262000.0 for Q1 2025 and $209000.0 for Q4 2024.